ArticleContrast media & molecular imaging2017
Erbium-Based Perfusion Contrast Agent for Small-Animal Microvessel Imaging.
Article in Contrast media & molecular imaging, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 14 citations in OpenAlex.
- Holmium vanadate nanoparticles as a biosafe and efficient contrast agent for spectral CT imaging of gastritis and colitis.Regenerative biomaterials · 2026Article
- Potential Applications of Rare Earth Metal Nanoparticles in Biomedicine.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Visualization of Small Vessels by Micro-Computed Tomography Using Titanium Dioxide Nanoparticles as a Novel Contrast Agent.International journal of biomedical imaging · 2025Article
- Nanomaterial-based CT contrast agents and their applications in image-guided therapy.Theranostics · 2023Review
- Article
- Dual-energy computed tomography using a gantry-based preclinical cone-beam microcomputed tomography scanner.Journal of medical imaging (Bellingham, Wash.) · 2018Article
- Corrigendum to "Erbium-Based Perfusion Contrast Agent for Small-Animal Microvessel Imaging".Contrast media & molecular imaging · 2018Article
Corrections and comments
- Erratum issued
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Micro-computed tomography (micro-CT) facilitates the visualization and quantification of contrast-enhanced microvessels within intact tissue specimens, but conventional preclinical vascular contrast agents may be inadequate near dense tissue (such as bone). Typical lead-based contrast agents do not exhibit optimal X-ray absorption properties when used with X-ray tube potentials below 90 kilo-electron volts (keV). We have developed a high-atomic number lanthanide (erbium) contrast agent, with a K-edge at 57.5 keV. This approach optimizes X-ray absorption in the output spectral band of conventional microfocal spot X-ray tubes. Erbium oxide nanoparticles (nominal diameter < 50 nm) suspended in a two-part silicone elastomer produce a perfusable fluid with viscosity of 19.2 mPa-s. Ultrasonic cavitation was used to reduce aggregate sizes to <70 nm. Postmortem intact mice were perfused to investigate the efficacy of contrast agent. The observed vessel contrast was >4000 Hounsfield units, and perfusion of vessels < 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.